Open Access

Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores

  • Chao-Wei Hsu1,
  • Kung-Hao Liang1,
  • Shiu-Feng Huang2,
  • Kuo-Chien Tsao3, 4 and
  • Chau-Ting Yeh1Email author
Contributed equally
BMC Research Notes20136:212

Received: 27 December 2012

Accepted: 23 May 2013

Published: 27 May 2013



Despite the availability of patented non-invasive methods, evaluation of the degrees of liver fibrosis remains difficult when conducting a retrospective study. Such inadequacy is largely caused by requirement of biochemical parameters rarely performed in routine clinical tests. We developed a novel fibrosis HB-F score using commonly performed tests for HBV infected patients.


424 patients with chronic HBV infection were included. Using clinical and virological data, HB-F score was developed from a training cohort (n = 213) and validated in a separate cohort (n = 211). The performance was compared with five other unpatented scores using ROC curves.


Univariate and multivariate analysis revealed that age, AST/ALT ratio, platelet count and prothrombin time prolongation were significantly associated with the ISHAK fibrosis score, and were used to calculate the HB-F score. When HB-F was used to assess prominent fibrosis and cirrhosis, the AUC was 0.81 and 0.80 respectively in the training cohort, and 0.80 and 0.76 respectively in the validation cohort. HB-F had the highest AUC compared with other scores. Furthermore, in assessing paired liver biopsies with increase or decrease of ISHAK scores, HB-F showed significant change in the same direction.


A new non-invasive score was developed, which could be used to assess severity of liver fibrosis in retrospective longitudinal studies in HBV patients.


Hepatitis B Fibrosis Score Receiver operation characteristic curve


It has been estimated that 350 millions patients are infected by hepatitis B virus (HBV) worldwide [1]. Chronic HBV infection may lead to severe sequelae such as liver fibrosis and cirrhosis [1]. Liver fibrosis is a progressive damage which not only impairs liver functions but also increases the risk of hepatocellular carcinoma [2]. The progression of fibrosis has multiple stages which are commonly defined by ISHAK or METAVIR scoring systems [35]. An advanced fibrosis score represents a serious clinical condition which requires careful medical managements. To prevent disease progression, we need to detect liver fibrosis at an earlier stage and to provide adequate antiviral agent treatment [6]. In the past decades, liver biopsy has been a gold standard for the assessment of fibrosis stages. However, there are several limitations when applying this method, such as sampling bias, low platelet counts, prolonged prothrombin time, massive ascites, patient’s intention and compliance as well as scoring variations from different pathologists [7]. Thus, other methods to accurately assess liver fibrosis are continuously sought, especially for non-invasive tests.

Ultrasound is one possible alternative for non-invasive assessment. FibroScan and Acoustic radiation force impulse (ARFI) elastography have been used for evaluation of fibrosis in chronic hepatitis B or C patients. However, it was found that the accuracy of FibroScan and ARFI was greatly interfered by higher degrees of necroinflammation and more advanced stages of fibrosis or cirrhosis especially in chronic hepatitis B patients [811].

Recently, a number of fibrosis scores have been proposed as surrogates to liver biopsy. These scores are often composed of a combination of biochemistry measurements and clinical parameters. For example, the AAR score is based on the ratio of aspartate transaminase (AST) and alanine transaminase (ALT) values [12]. The APRI score is the AST value divided by platelet counts [13]. The early AAR and APRI scores motivate several subsequent scores where the ratios of AST/ALT or AST/platelet counts are employed as part of their equations. The Fibrosis index (FI) score is composed of platelet counts and serum albumin [14]. The Fibroindex consists of AST, platelets, and gamma globulin measurements [15]. The FIB-4 index includes age, AST, ALT and platelet counts [16, 17]. A patented test, named FibroTest, is composed of alpha2-macroglobulin, haptoglobin, gamma glutamyl transpeptidase (GGT), age, bilirubin, apoA1, and sex. Most of these markers were initially derived from patients with chronic hepatitis C but were subsequently tested in chronic hepatitis B patients. Meta-analysis for the performance of biomarkers in HBV or hepatitis C virus (HCV) infection showed that assessment of the treatment efficacy on fibrosis progression was equally effective when estimated by either FibroTest or biopsy. Despite the great performance of FibroTest, there were still no sufficient data to show that biomarker or biopsy alone could make accurate fibrosis staging in patients with chronic HBV infection [18]. Furthermore, the requirement of measuring several uncommon tests to calculate the score greatly limited its use in retrospective study [1921]. We were thus motivated to formulate a new hepatitis B-fibrosis score (HB-F) using commonly performed tests and clinical data in a large cohort of chronic HBV infected patients.


Patients and samples

Under approval of Institutional Review Board, Chang Gung Medical Council, this study was conducted at Liver Research Center, Chang Gung Memorial Hospital, Taiwan. A total of 424 adult patients with compensated chronic hepatitis B were recruited (Table 1). All of them have signed informed consent forms. They received liver biopsy between January 2007 and July 2009. No antiviral agents were given to these patients before biopsy was taken and patients with other viral co-infections, such as HIV, hepatitis C or hepatitis D co-infections were pre-excluded. Hepatitis B e Antigen (HBeAg) and antibodies to HBeAg (anti-HBe) were measured before liver biopsy. Biochemistry were assessed at the same time of liver biopsy, including AST, ALT, bilirubin, gamma glutamyl transpeptidase (GGT), albumin, alpha-1 globulin, alpha-2 globulin, beta globulin, gamma globulin and albumin/globulin ratio. Hematology tests were also performed at same time point, including hemoglobin, platelet count, white blood cell, prothrombin time, and alpha-fetoprotein (AFP).
Table 1

Basic clinicopathological data for hepatitis B patients included


Training cohort



(n = 213)

cohort (n = 211)

Age at biopsy in years, mean ± SD

44.4 ± 11.8

45.6 ± 11.4

Male, n (%)

179 (84)

175 (83)



Necroinflammation score, mean ± SD

  Periportal inflammation

1.0 ± 0.8

0.9 ± 0.8

  Confluence necrosis

0.3 ± 1.0

0.2 ± 0.8

  Focal inflammation

1.9 ± 0.7

2.0 ± 0.7

  Portal inflammation

2.2 ± 1.0

2.2 ± 0.9

ISHAK fibrosis score, n (%)



1 (1)

1 (1)


28 (13)

28 (13)


32 (15)

32 (15)


70 (33)

71 (34)


21 (10)

21 (10)


46 (22)

45 (21)


15 (7)

13 (6)

HBeAg-positive, n (%)

109 (51)

91 (43)

Biochemistry, mean ± SD



91.3 ± 83.6

94.9 ± 100.1


170.1 ± 173.8

166.2 ± 177.9


0.6 ± 0.3

0.6 ± 0.3

AFP (ng/mL)

10.5 ± 22.2

20.4 ± 82.0

Bilirubin (mg/dL)

1.0 ± 0.7

1.0 ± 0.4


69.0 ± 77.0

60.1 ± 57.3

Albumin (g/dL)

4.6 ± 0.3

4.5 ± 0.4

Platelet (×103/mm3)

188.2 ± 54.2

189.2 ± 49.4

Prothrombin time prolongation (sec)

1.0 ± 0.6

1.0 ± 0.8

White blood cell (×103/mm3)

5.7 ± 1.7

5.5 ± 1.6

Hemoglobin (g/dL)

15.1 ± 1.4

15.2 ± 1.3

Alpha-1 globulin (g/dL)

0.2 ± 0.1

0.2 ± 0.0

Alpha-2 globulin (g/dL)

0.8 ± 0.2

0.8 ± 0.1

Beta globulin (g/dL)

0.8 ± 0.1

0.7 ± 0.1

Gamma globulin (g/dL)

1.5 ± 0.4

1.4 ± 0.4


1.5 ± 0.3

1.5 ± 0.3

Histologic evaluation of biopsy samples were carried out at the Pathology Department, according to ISHAK’s staging system, which had seven severity levels: FS0 (no fibrosis), FS1 (fibrous expansion of some portal areas), FS2 (fibrous expansion of most portal areas), FS3 (fibrous expansion of most portal areas with occasional portal to portal bridging), FS4 (fibrous expansion of most portal areas with marked bridging), FS5 (marked bridging with occasional nodules, incomplete cirrhosis), and FS6 (cirrhosis).

After biopsy, subjects of each ISHAK stage were randomly assigned into two cohorts: the training cohort (n = 213) and the validation cohort (n = 211), for formula-deriving and validation purposes respectively. This way, subjects were evenly split across all ISHAK stages. Clinical parameters and biochemistry measurements were individually tested for their association to the ISHAK fibrosis stages. The associated factors were then combined to produce the HB-F score. The score was then validated using the validation cohort, and its performance was compared with five other reported scores (AAR, FIB-4, FI, APRI, Fibroindex), which were all originally derived from hepatitis C infected patients.

Statistical analysis

Clinicopathological data distribution was compared between the training and validation cohorts by either Chi-square tests or two-sample t-tests with unequal variance. Linear regression was used for the univariate and multivariate analysis to assess the association between the clinical/ laboratory parameters and ISHAK fibrosis scores. Significance levels of correlation were assessed by Wald test statistics. All the P-values were two-tailed. The Receiver Operating Characteristic (ROC) Curve was used to examine the trade-off of sensitivity and specificity. The performance of classification was assessed by the Area Under Curve (AUC). The HB-F and FIB-4 scores of the two biopsy examinations were assessed by paired t-tests.


The distributions of subjects’ clinicopathological values were presented in Table 1. The two cohorts had similar number of subjects across all ISHAK stages without significant disparity (P = 1.000). Additionally, comparison of the age, gender, inflammation scores and the biochemistry and hemogram values revealed no significant difference.

Univariate and multivariate associations of various factors to ISHAK fibrosis stages were performed in the training cohort (Table 2). Significant associations were found in eight parameters, including age at biopsy, HBeAg, AST/ALT ratio, AFP, GGT, Albumin, platelet and prothrombin time prolongation (P < 0.05). Among them, four parameters (age at biopsy, AST/ALT ratio, platelet and prothrombin time prolongation) showed stronger association (P < 0.001). A multivariate analysis of the four parameters showed that all of them remained significant (P < 0.05), indicating their independent association to the ISHAK fibrosis stages.
Table 2

Univariate and multivariate analysis for factors associated with liver fibrosis


Beta (95% CI)


Adjusted beta (95% CI)


Age at biopsy

0.035 (0.018, 0.052)

< 0.001

0.018 (0.001, 0.036)



0.046 (-0.597, 0.506)




-0.496 (-0.943, -0.048)




0.001 (-0.001, 0.004)




0.000 (-0.001, 0.001)




1.881 (1.199, 2.563)

< 0.001

1.085 (0.368, 1.803)


AFP (ng/mL)

0.012 (0.001, 0.023)



Bilirubin (mg/dL)

0.142 (-0.168, 0.452)




0.006 (0.002, 0.009)



Albumin (g/dL)

-1.440 (-2.839, -0.042)



Platelet (×103/mm3)

-0.012 (-0.015, -0.009)

< 0.001

-0.009 (-0.013, -0.005)

< 0.001

Prothrombin time prolongation (sec)

0.781 (0.404, 1.157)

< 0.001

0.449 (0.098, 0.800)


White blood cell (×103/mm3)

0.049 (-0.093, 0.192)



Hemoglobin (g/dL)

0.053 (-0.125, 0.231)



Alpha-1 globulin (g/dL)

-0.898 (-2.683, 0.886)



Alpha-2 globulin (g/dL)

-0.505 (-1.746, 0.736)



Beta globulin (g/dL)

-0.808 (-2.160, 0.545)



Gamma globulin (g/dL)

0.214 (-0.327, 0.754)




-0.422 (-1.180, 0.335)



The four parameters were then linearly combined to generate the HB-F score using the multiple regression coefficients (Adjusted Beta) in Table 2, omitting the constant term. The formula of HB-F score was written as:

HB-F = 0.018 × [Age] + 1.085 × [AST/ALT] - 0.009 × [Platelet (×103/mm3)] + 0.449 × [Prothrombin time prolongation (sec)]

In the training cohort, subjects with a more severe fibrosis stage also had a higher range of HB-F score (Figure 1). The score was then used to classify patients with (FS > =5) or without cirrhosis (FS <5) and patients with (FS > =4) or without severe fibrosis (FS < 4). The AUCs were 0.810 and 0.799 for the distinction of severe fibrosis and cirrhosis, respectively, in the training cohort. Consistently, the corresponding AUCs were 0.797 and 0.757 respectively in the verification cohort. Both AUCs were larger than 0.75 suggesting adequate capability of HB-F in identifying severe fibrosis subjects (Figure 1).
Figure 1

Performance of the HB-F fibrosis score in the training cohort of patients. (A) The ranges of HB-F scores in patients with different ISHAK fibrosis score (FS1-FS6). Gray boxes represented the 25%-75% quartiles; The middle horizontal lines represented the median scores. (B) The ranges of HB-F scores in subjects stratified by FS < 5 (non-cirrhotic patients) and FS > =5 (cirrhosis) (P < 0.001). (C) The ranges of HB-F scores in subjects grouped by FS < 4 and FS > =4 (prominent fibrosis) (P < 0.001). (D) The ROC curve of the HB-F score for the diagnosis of cirrhosis patients (AUC = 0.799). (E) The ROC curve for the diagnosis of prominent fibrosis patients (AUC = 0.810).

When compared with five other reported methods, HB-F had the highest AUC (Table 3, Figure 2). The next three best scoring methods were FIB-4, Fibroindex and APRI, respectively, but all had no statistically significant difference when compared with HB-F score. AAR, on the other hand, had a significantly inferior performance in classifying both the cirrhosis and prominent fibrosis. FI had an inferior performance in identifying prominent fibrosis. The ROCs of all the methods were presented in Figure 2.
Table 3

Performance of six fibrosis score for evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B

Non-invasive index

AUC (95% CI)

Difference between areas (95% CI)*


Prominent fibrosis


HB-F (training)

0.810 (0.751, 0.861)


HB-F (verification)

0.797 (0.737, 0.849)



0.772 (0.709, 0.826)

0.0255 (-0.0236, 0.0746)



0.767 (0.704, 0.822)

0.0301 (-0.0298, 0.0899)



0.753 (0.689, 0.810)

0.0439 (-0.0302, 0.1180)



0.630 (0.561, 0.696)

0.1670 (0.0947, 0.2390)

< 0.0001


0.724 (0.659, 0.784)

0.0728 (0.0093, 0.1360)




HB-F (training)

0.799 (0.739, 0.851)


HB-F (verification)

0.757 (0.694, 0813)



0.727 (0.662, 0.786)

0.0297 (-0.0223, 0.0818)



0.722 (0.656, 0.781)

0.0351 (-0.0320, 0.1020)



0.698 (0.631, 0.759)

0.0589 (-0.0244, 0.1400)



0.636 (0.568, 0.701)

0.1210 (0.0470, 0.1950)



0.717 (0.651, 0.777)

0.0403 (-0.0283, 0.1090)


*Comparison between the AUC of HB-F (verification cohort) and those of the other scoring methods.

Figure 2

The ROC curves of HB - F score and 5 other methods (AAR, FIB - 4, FI, APRI, and Fibroindex) for the diagnosis of prominent fibrosis (left) or cirrhosis (right) in the validation cohort.

A total of 33 subjects had received a second biopsy and biochemistry examinations. They offered additional disease progression and remission data for evaluating the change of HB-F and FIB-4 score under an increase or decrease of ISHAK levels (Figure 3). FIB-4 was chosen because it had the highest AUC among the benchmark scores. The HB-F scores showed significant changes in the same direction of an increment (P = 0.011) and decrement (P = 0.015) of ISHAK levels. In contrast, FIB-4 did not show such a correlated change.
Figure 3

Comparison of HB - F and FIB - 4 scores in determination of improvement or deterioration of liver fibrosis in paired biopsies. Left, The second biopsy showed an increase of ISHAK fibrosis level (n = 12). Middle, The second biopsy showed an decrease of ISHAK fibrosis level (n = 8). Right, The second biopsy showed the same ISHAK fibrosis level (n = 13).


In this study, a novel fibrosis score named HB-F was formulated, by combination of four factors which was highly significant in the association with ISHAK fibrosis stages (P < 0.001). The HB-F score was developed from a large cohort of HBV-infected patients, as HBV infection is a major etiology of fibrosis in Taiwan. Although the study also included other HBV-related factors such as the presence or absence of HBeAg, this factor only manifested marginal association to the ISHAK stages (P = 0.03). Hence, the HBV-related factors were not included in HB-F.

The four factors in HB-F score included age, the AST/ALT ratio from biochemistry test, platelet count and prothrombin time prolongation from hematological test. The prothrombin time prolongation was the only factor not previously included in other scores. Our multivarite analysis suggested that it was an independently associated factor to liver fibrosis. One limitation of this study is that the performance is only assessed in HBV-related patients. This is due to the high prevalence of HBV infection in Taiwan and thus a need to develop reliable fibrosis score for retrospective studies. Nevertheless, the four factors in the equation are not HBV-specific. Therefore, this score may be used to evaluate the fibrosis of other etiologies such as HCV infection and alcohol, once the corresponding validation is completed in these subjects.

The proposed HB-F score was constructed by multiple regression coefficients (Adjusted Beta). It is a challenge for both pathologists and fibrosis scores alike to discern the stage of early fibrosis (FS1 to FS3). This is also a limitation of HB-F. However, Figure 1A showed the distribution of HB-F score increased as the ISHAK-stage ascended from FS1 to FS2. This observation suggested that HB-F might potentially be used for classifying the very earlier stage fibrosis. A larger number of patients in these two stages are needed for verification.

The HB-F score had superior performance than five other HCV-derived scores in identifying both the prominent fibrosis and cirrhosis patients, when assessed by AUCs. However, FIB-4, Fibroindex and APRI all showed very similar performance as in Figure 2 and Table 3, particularly FIB-4 seemed to be almost equally effective. However, when the scores were evaluated using paired liver biopsies, HB-F proved to be a better score for judgment of histology improvement or deterioration. Additionally, a similar performance between HB-F and other previous scores (FIB-4, FI, Fibroindex) suggested that we could use these scores interchangeably for estimation of fibrosis severity in retrospective studies where several clinical parameters were missing for one of these scores. In other words, our studies and the novel score provided flexibility for retrospective studies where fibrosis evaluation was often limited by data availability.


In conclusion, we have formulated a new fibrosis score, the HB-F, for chronic hepatitis B patients, by use of a linear combination of age, AST/ALT ratio, platelet count and prothrombin time prolongation values. Judging from the AUC comparison, HB-F score is better than other existing unpatented scores derived from hepatitis C patients.






Alanine transaminase


Aspartate transaminase


Area under the curve


Fibrosis index


Gamma glutamyl transpeptidase


Hepatitis B-fibrosis


Hepatitis B virus


Hepatitis C virus


Receiver operation characteristic.


Authors’ Affiliations

Liver Research Center, Chang Gung Memorial Hospital
Department of Pathology, Chang-Gung Memorial Hospital
Department of Medical Biotechnology and Laboratory Science, Research Center for Emerging Viral Infections, Chang Gung University
Departments of Laboratory Medicine, Chang Gung Memorial Hospital


  1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004, 11: 97-107. 10.1046/j.1365-2893.2003.00487.x.PubMedView ArticleGoogle Scholar
  2. Bataller R, Brenner DA: Liver fibrosis. J Clin Invest. 2005, 41: 1046-1055.Google Scholar
  3. Ishak K, Baptista A, Bianchi L: Histologic grading and staging of chronic hepatitis. J Hepatol. 1995, 22: 696-699. 10.1016/0168-8278(95)80226-6.PubMedView ArticleGoogle Scholar
  4. Knodell RG, Ishak KG, Black WC: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981, 1: 431-435. 10.1002/hep.1840010511.PubMedView ArticleGoogle Scholar
  5. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology. 1996, 24: 289-293. 10.1002/hep.510240201.PubMedView ArticleGoogle Scholar
  6. Liaw YF, Sung JJ, Chow WC: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004, 351: 1521-1531. 10.1056/NEJMoa033364.PubMedView ArticleGoogle Scholar
  7. Goodman ZD: Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007, 47: 598-607. 10.1016/j.jhep.2007.07.006.PubMedView ArticleGoogle Scholar
  8. Ferrailoi G, Tinelli C, Malfitano A: Performance of real-time strain elastography, transient elastography, and aspartate-to-platelet ratio index in the assessment of fibrosisi in chronic hepatitis C. Am J Roentgenol. 2012, 199: 19-25. 10.2214/AJR.11.7517.View ArticleGoogle Scholar
  9. Kim SU, Lee JH, Kim Do Y: Prediction of liver–related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One. 2012, 7: e36676-10.1371/journal.pone.0036676.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Yoon KT, Lim SM, Park JY: Liver stiffiness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci. 2012, 57: 1682-1691. 10.1007/s10620-012-2044-4.PubMedView ArticleGoogle Scholar
  11. Cardoso AC, Carvalho-Filho RJ, Stern C: Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012, 32: 612-621. 10.1111/j.1478-3231.2011.02660.x.PubMedView ArticleGoogle Scholar
  12. Williams AL, Hoofnagle JH: Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis: relationship to cirrhosis. Gastroenterology. 1988, 95: 734-739.PubMedGoogle Scholar
  13. Wai CT, Greenson JK, Fontana RJ: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003, 38: 518-526.PubMedView ArticleGoogle Scholar
  14. Ohta T, Sakaguchi K, Fujiwara A: Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama. 2006, 60: 77-84.PubMedGoogle Scholar
  15. Koda M, Matunaga Y, Kawakami M: FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology. 2007, 45: 297-306. 10.1002/hep.21520.PubMedView ArticleGoogle Scholar
  16. Sterling RK, Lissen E, Clumeck N: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006, 43: 1317-1325. 10.1002/hep.21178.PubMedView ArticleGoogle Scholar
  17. Vallet-Pichard A, Mallet V, Nalpas B: FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology. 2007, 46: 32-36. 10.1002/hep.21669.PubMedView ArticleGoogle Scholar
  18. Poynard T, Ngo Y, Munteanu M: Biomarkers of liver injury for hepatitis clinical trial: a meta-analysis of longitudinal studies. Antivir Ther. 2010, 15: 617-631. 10.3851/IMP1570.PubMedView ArticleGoogle Scholar
  19. Stibbe KJ, Verveer C, Francke J: Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroentero. 2011, 46: 962-972. 10.3109/00365521.2011.574725.View ArticleGoogle Scholar
  20. Poynard T, Ngo Y, Munteanu M: Noninvasive markers of hepatitis fibrosis in chronic hepatitis B. Curr Hepat Rep. 2011, 10: 87-97. 10.1007/s11901-011-0096-0.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Kim BK, Kim SU, Kim HS: Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012, 7: e35825-10.1371/journal.pone.0035825.PubMedPubMed CentralView ArticleGoogle Scholar


© Hsu et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.